Use of chemotherapy for treatment of a mixed-cell thoracic lymphoma in a horse.

The research article presents a case study of a 4-year-old Oldenburg mare that was diagnosed with lymphoma and successfully treated with chemotherapy. The focus of the study is on the use of chemotherapeutic protocols for treating thoracic lymphoma in horses, particularly when conventional diagnostic processes are not possible.

Introduction and Diagnosis

The discussed case is about a mare who initially showed symptoms of lower airway disease and later developed bilateral pleural effusion, a condition where fluid accumulates around the lungs. The diagnosis process posed several challenges. Initially:

• Fluid samples were taken from the mare’s chest cavity (thoracocentesis). However, no cancerous (neoplastic) cells were identified.
• A radiographic examination revealed a mass in the thorax area but its location made tissue sampling impossible.

The diagnosis of lymphoma was eventually confirmed through a process known as immunophenotyping which involved analyzing the composition of the fluid in the mare’s pleural cavity.

Chemotherapy Treatment and Results

Due to limited data regarding chemotherapy-induced remission in horses, treating mixed-cell thoracic lymphoma presented a significant challenge. Nonetheless, a chemotherapy treatment was performed, involving the administration of:

• Cytarabine
• Cyclophosphamide
• Prednisolone

The treatment caused no adverse side effects and led to the horse’s remission, demonstrating the potential efficacy of this chemotherapeutic protocol in tackling thoracic lymphoma.

Conclusions and Implications

The study underscores the value of immunophenotyping in diagnosing lymphoma, especially when other diagnostic techniques like invasive tissue extraction are not suitable. This case provides valuable information about using chemotherapy for treating thoracic lymphoma in horses, suggesting that administration of cytarabine, cyclophosphamide, and prednisolone can lead to remission. This could be particularly helpful for veterinary medicine and the development of therapeutic approaches for lymphoma in horses. The possible lack of adverse effects also indicates the potential safety of this chemotherapy protocol.